TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26724641
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/d) plus placebo
Study: 18612534
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (specific dosage and duration not mentioned)
Study: 18612534
Drug: Risk score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk score based on six variables (age >75 years, recent bleeding, cancer, creatinine levels >1.2 mg/dl, anemia, pulmonary embolism)
Study: 10392324
Drug: Inhaled triamcinolone
Normalized name: triamcinolone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triamcinolone acetonide (800 mcg)
Study: 10392324
Drug: Intravenous triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous triamcinolone acetonide (400 mcg)
Study: 10392324
Drug: Inhaled triamcinolone
Normalized name: triamcinolone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triamcinolone acetonide (800 mcg) with oral charcoal
Study: 8721464
Drug: Patient-controlled premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled premedication by i.v. midazolam (mean dose 0.7 mg, 0.7-1.1 mg for anxious patients, 1.7 mg for those using the device)
Study: 8721464
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 4 mg i.v. midazolam (1-hour infusion)
Study: 30058609
Drug: Procedures for
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Procedures for estimating biological occupational exposure limits (BOELs) using regression analysis on 14 organic solvents.
Study: 19393473
Drug: Pamidronate, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate, 1 mg/kg, perioperatively and then at 1, 4, 8, and 12 months
Study: 8397999
Drug: One pill
Normalized name: Geone Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill each day for < or = 63 weeks
Study: 3522347
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride treatment
Study: 29984564
Drug: Aquatic physical
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic physical training (APT) performed twice a week for 16 weeks
Study: 17052967
Drug: G-CSF during
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF during radiotherapy (group B)
Study: 3081399
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drugs
Study: 24646858
Drug: Mean baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean baseline 24‐h urinary sodium excretion of 3.46 g/day
Study: 24646858
Drug: Urine sodium
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine sodium under 3 g/day
Study: 24646858
Drug: Urine sodium
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine sodium ⩾ 3 g/day
Study: 18988091
Drug: SPF50 sunscreen
Normalized name: ZINC OXIDE 225 mg in 1 mL TOPICAL LOTION [People4Ocean SPF50 sunscreen]
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF50 sunscreen lotion
Study: 18988091
Drug: SPF50 sunscreen
Normalized name: ZINC OXIDE 225 mg in 1 mL TOPICAL LOTION [People4Ocean SPF50 sunscreen]
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF50 sunscreen spray lotion
Study: 16195164
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of the herbal remedy made from Rosa canina daily for 3 months
Study: 9505981
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 3350/electrolyte solution
Study: 8445442
Drug: Ethamsylate (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethamsylate (12.5 mg/kg) given prophylactically within the first 4 hours of life followed by 6-hourly doses for 4 days
Study: 31409166
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (400 mg cyclogest vaginal suppositories once daily)
Study: 31409166
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (250 mg of 17-hydroxyprogesterone caproate weekly)
Study: 25392319
Drug: Subcutaneous Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Interferon beta (IFNb)
Study: 25392319
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biomarkers (CASP2/IRF4/IRF6)
Study: 25392319
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biomarkers (CASP2/IL10/IL12Rb1)
Study: 20558036
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug with no side effects, no additional visit required, balanced information provided, results in the public domain, project approved by a research ethics committee.
Study: 16544149
Drug: Endo-anal pudendal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endo-anal pudendal nerve stimulation daily at home with a portable home unit
Study: 8558203
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (5 mg/kg bolus over 3 hours followed by 15 mg/kg infusion over 24 hours) plus paclitaxel (200 mg/m2 over 3 hours)
Study: 6353927
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg relaxin
Study: 6353927
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg relaxin
Study: 30770754
Drug: L-AA
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [WL-AAB-Z-W-330]
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AA
Study: 21331637
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish (5% sodium fluoride, Duraphat(®), Colgate) applied monthly for 6 months
Study: 21331637
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (control) applied monthly for 6 months
Study: 19458299
Drug: Straight-tip Tenckhoff
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Straight-tip Tenckhoff catheter with an artificial subcutaneous swan neck (TC)
Study: 17635844
Drug: 1.87 mg
Normalized name: proline 1.87 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.87 mg triptorelin depot i.m. followed by daily s.c. injections of saline
Study: 17635844
Drug: Reduced-dose daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose daily buserelin (0.5 mg initially, reduced to 0.25 mg)
Study: 11579354
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of oral conjugated estrogens (Premarin) per day for 4 to 6 weeks
Study: 9848785
Drug: Irbesartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (100 mg/d)
Study: 9848785
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg/d) + Indomethacin (75 mg twice a day)
Study: 9848785
Drug: Irbesartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (100 mg/d) + Indomethacin (75 mg twice a day)
Study: 28967201
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin with 150 mg aclatonium once daily for 8 weeks
Study: 28967201
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin with placebo once daily for 8 weeks
Study: 25382452
Drug: Carvedilol (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (titrated from 3.125 mg twice daily to 6.25 mg twice daily)
Study: 23237631
Drug: Acenocoumarol dosing
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol dosing algorithm based on demographic, clinical, and pharmacogenetic variables (VKORC1, CYP2C9, CYP4F2, ApoE)
Study: 23237631
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (control group) with scheduled and adjusted acenocoumarol dose following common clinical practice
Study: 23237631
Drug: Acenocoumarol dosing
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol dosing algorithm
Study: 17876425
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with intravenous midazolam (5 mg for those under 65 years, 2.5 mg for those aged 65 years or more)
Study: 16230678
Drug: PVI FU
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVI FU 225 mg/m2/d for 5 d/wk for six cycles during RT
Study: 11988242
Drug: Interferon beta‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1b 250 microg administered every other day
Study: 11988242
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a 30 microg administered once a week
Study: 7569506
Drug: Dose-response information
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response information to support drug registration (especially dose/toxicity relationships)
Study: 7569506
Drug: ICH Draft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICH Draft Guideline 3 on the extent of population exposure required to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions
Study: 1978233
Drug: bopindolol (1‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol (1‐3 mg daily)
Study: 1978233
Drug: metoprolol (100‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (100‐300 mg daily in two divided doses)
Study: 336412
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone (LH-RH)
Study: 336412
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (LH-RH, hCG, and placebo)
Study: 29119732
Drug: Warfarin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (Group W, n=30)
Study: 29119732
Drug: Warfarin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (Group W)
Study: 22985692
Drug: Inhaled aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aztreonam lysine (AZLI) 75 mg (three-times/day)
Study: 22985692
Drug: Inhaled tobramycin
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin nebulizer solution (TNS) 300 mg (twice/day)
Study: 16764551
Drug: Placebo techniques
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo techniques developed to mimic spinal manipulative therapy
Study: 11713618
Drug: Olanzapine 2.5
Normalized name: olanzapine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 2.5 mg and 5 mg
Study: 1089913
Drug: Clonazepam (0.028
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.028 to 0.111 mg/kg)
Study: 28760794
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist trigger and single vitrified-warmed blastocyst transfer in a subsequent hCG triggered natural menstrual cycle
Study: 21525194
Drug: Galactooligosaccharides 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactooligosaccharides 2.5 g
Study: 21525194
Drug: Galactooligosaccharides 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactooligosaccharides 5.0 g
Study: 21525194
Drug: Galactooligosaccharides 0
Normalized name: fructooligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactooligosaccharides 0 g (Control)
Study: 11530125
Drug: Mifepristone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 100 mg followed by misoprostol 400 microg orally (group 1)
Study: 11530125
Drug: Mifepristone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 100 mg followed by misoprostol 800 microg vaginally (group 2)
Study: 12959295
Drug: Nifedipine with
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine with grapefruit juice (200 ml double strength)
Study: 12959295
Drug: Nifedipine with
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine with quercetin (400 mg)
Study: 3126890
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (n = 32)
Study: 3126890
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy (n = 30)
Study: 3126890
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (n = 30)
Study: 28350652
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (topical application during surgery)
Study: 25015650
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (RAT) - 3 conventional therapy sessions and 2 robot-assisted sessions per week over 8 weeks
Study: 25015650
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy - 5 sessions per week over 8 weeks
Study: 21205399
Drug: Oportunidades food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oportunidades food supplement (OFS)
Study: 8993761
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of anti-herpes dialysate (AH-DLE)
Study: 8993761
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of anti-herpes dialysate (AH-DLE)
Study: 8993761
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of anti-herpes dialysate (AH-DLE)
Study: 6379630
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray (100 micrograms into each nostril twice daily)
Study: 6379630
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate pressurized nasal spray (100 micrograms into each nostril twice daily)
Study: 21902621
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) 75 mg qd then 25 mg qd
Study: 21902621
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) 600 mg qd
Study: 20935517
Drug: Monovalent A
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent A (H1N1) pandemic vaccine (Panenza®)
Study: 20935517
Drug: Trivalent split
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent split inactivated vaccine (Vaxigrip®)
Study: 18595959
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide (32 microg per nostril at bedtime)
Study: 16208072
Drug: Drug misuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug misuse and abuse prevention program (1 hour, once a week for 5 weeks)
Study: 10999082
Drug: Sequential Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Drug Monotherapy (SDM)
Study: 10999082
Drug: Step Care
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step Care Therapy (SCT)
Study: 8527293
Drug: Lactose (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (various doses)
Study: 8527293
Drug: Placebo (empty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (empty dose)
Study: 2255839
Drug: Ivermectin 50
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 50 mcg/kg
Study: 28098838
Drug: Silymarin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (oral doses)
Study: 19479385
Drug: Satranidazole mucoadhesive
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Satranidazole mucoadhesive gel (SC30 formulation)
Study: 19479385
Drug: Marketed metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marketed metronidazole gel (Metrogyl gel)
Study: 3221374
Drug: Nitrendipine 10-20
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10-20 mg per day
Study: 3221374
Drug: Oxprenolol 160
Normalized name: oxprenolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 160 mg per day
Study: 30231990
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (LDRT) - 6 × 1 Gy in 2 weeks
Study: 30231990
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment - 6 × 0 Gy in 2 weeks
Study: 26418670
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and ribavirin treatment for 12 weeks (Finnish patients)
Study: 26418670
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and ribavirin treatment for 12-16 weeks (Swedish patients)
Study: 19034033
Drug: Ambroxol administered
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol administered orally for a week before and after surgery (n = 25)
Study: 8403177
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg sublingual triazolam
Study: 3709641
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of PY 108‐068
Study: 3709641
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of PY 108‐068
Study: 21798721
Drug: Ziprasidone (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (80-160 mg/d) plus mood stabilizer (lithium or valproate)
Study: 8677906
Drug: Ifosfamide 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 1.5 g/m2 and mesna at 30% of the ifosfamide dose, administered i.v. daily for 5 days every 21 days.
Study: 1815962
Drug: Verapamil (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (after oral pretreatment)
Study: 6824300
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine (3.5 ml)
Study: 6824300
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine (3 ml)
Study: 31271569
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A 0.05% (twice a day for 10 days before and 10 days after surgery)
Study: 31271569
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (31 patients who did not receive cyclosporine treatment)
Study: 12205259
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen 15 mg/kg (Group A)
Study: 12205259
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen 30 mg/kg (Group B)
Study: 12205259
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 15 mg/kg (Group C)
Study: 9809555
Drug: T-20 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-20 (100 mg twice daily)
Study: 9809555
Drug: T-20 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-20 (various doses)
Study: 7665721
Drug: Lornoxicam 32
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 32 mg
Study: 25369608
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (mean dose 7-9 g)
Study: 19432498
Drug: olmesartan/amlodipine 40/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan/amlodipine 40/5 mg
Study: 19432498
Drug: olmesartan/amlodipine 40/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan/amlodipine 40/10 mg
Study: 19432498
Drug: olmesartan/amlodipine/HCTZ 40/10/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan/amlodipine/HCTZ 40/10/12.5 mg
Study: 7060825
Drug: UDCA 12
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 12 mg/kg/day
Study: 7060825
Drug: UDCA 8
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 8 mg/kg/day
Study: 7060825
Drug: UDCA 4
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 4 mg/kg/day
Study: 22307572
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) in women in 2008
Study: 20973712
Drug: Aripiprazole (flexibly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (flexibly dosed 2-15 mg/day)
Study: 20973712
Drug: Aripiprazole (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (fixed dose 5, 10, or 15 mg/day)